Hatch-Waxman Act MCQs With Answer

Hatch-Waxman Act MCQs With Answer is designed to help M. Pharm students in Regulatory Affairs (MPH 104T) master the core concepts behind the U.S. generic drug approval framework. The Hatch-Waxman Act balances innovation and access by aligning patent protections with streamlined approval pathways like ANDA and 505(b)(2). This quiz covers key provisions such as patent certifications, exclusivities (5-year NCE, 3-year clinical, pediatric 6-month), the 180-day first-filer incentive, Orange Book listings, 30-month stays, and litigation mechanics including Paragraph IV certifications and use-code carve-outs. You’ll also encounter practical regulatory nuances like bioequivalence standards, therapeutic equivalence codes, suitability petitions, and the 505(q) citizen petition process. Each question is crafted to deepen understanding and sharpen exam readiness.

Q1. The Hatch-Waxman Act primarily establishes which regulatory pathway for generic small-molecule drugs?

• Abbreviated New Drug Application (ANDA) under section 505(j)
• Biologics License Application (BLA) under section 351(a)
• New Drug Application (NDA) under section 505(b)(1)
• Interchangeability application under section 351(k)

Correct Answer: Abbreviated New Drug Application (ANDA) under section 505(j)

Q2. Which certification in an ANDA asserts that a listed patent is invalid or will not be infringed by the generic product?

• Paragraph I certification
• Paragraph II certification
• Paragraph III certification
• Paragraph IV certification

Correct Answer: Paragraph IV certification

Q3. What is the standard bioequivalence criterion typically required for ANDA approval?

• 90% confidence interval of AUC and Cmax within 70–140%
• 90% confidence interval of AUC and Cmax within 80–125%
• Mean AUC and Cmax within 85–115% of reference
• Any single-dose Cmax within ±20% of reference

Correct Answer: 90% confidence interval of AUC and Cmax within 80–125%

Q4. Under the Hatch-Waxman framework, the first ANDA applicant to file a complete Paragraph IV certification against a listed patent may be eligible for:

• 3-year clinical investigation exclusivity
• 5-year new chemical entity (NCE) exclusivity
• 180-day generic marketing exclusivity
• 7-year orphan drug exclusivity

Correct Answer: 180-day generic marketing exclusivity

Q5. Filing a Paragraph IV certification requires the ANDA applicant to send notice letters to the NDA holder and patent owner within what timeframe?

• Within 20 days after FDA notifies the applicant that the ANDA is filed (substantially complete)
• Within 10 days after the initial pre-ANDA meeting
• Within 30 days after receiving tentative approval
• Within 45 days after the Orange Book patent is listed

Correct Answer: Within 20 days after FDA notifies the applicant that the ANDA is filed (substantially complete)

Q6. A 30-month stay of approval is typically triggered when:

• The NDA holder files a citizen petition within 30 days of ANDA filing
• The NDA holder or patent owner sues the ANDA applicant within 45 days of receiving a Paragraph IV notice
• FDA issues a refuse-to-receive letter
• The first-filer launches an authorized generic

Correct Answer: The NDA holder or patent owner sues the ANDA applicant within 45 days of receiving a Paragraph IV notice

Q7. Which exclusivity prevents FDA from accepting (i.e., receiving) an ANDA or 505(b)(2) for 5 years, with a possible 4-year exception for Paragraph IV filings?

• 3-year new clinical investigation exclusivity
• 5-year new chemical entity (NCE) exclusivity
• Pediatric exclusivity
• Orphan drug exclusivity

Correct Answer: 5-year new chemical entity (NCE) exclusivity

Q8. Which statement best describes 505(b)(2) applications under Hatch-Waxman?

• They must be pharmaceutically identical to the RLD and rely solely on bioequivalence
• They rely partly on FDA’s previous findings or literature while including new data to support differences
• They are reserved exclusively for biologics
• They cannot include any proprietary data or bridging studies

Correct Answer: They rely partly on FDA’s previous findings or literature while including new data to support differences

Q9. Which of the following patents is eligible for Orange Book listing for a small-molecule drug?

• Process (manufacturing) patent
• Packaging configuration patent unrelated to the drug
• Method-of-use patent that covers an approved indication
• Equipment patent used for synthesis

Correct Answer: Method-of-use patent that covers an approved indication

Q10. A section viii (carve-out) statement in an ANDA is used to:

• Dispute Orange Book patent listing accuracy in court
• Avoid infringing a listed method-of-use patent by omitting the protected indication from labeling
• Trigger a 30-month stay while litigation proceeds
• Claim 180-day exclusivity

Correct Answer: Avoid infringing a listed method-of-use patent by omitting the protected indication from labeling

Q11. Which therapeutic equivalence (TE) code generally indicates that actual or potential bioequivalence issues have been resolved and the product is substitutable?

• AB
• BX
• B*
• NR

Correct Answer: AB

Q12. After the 2003 MMA amendments, the 180-day exclusivity period for first applicants generally begins:

• On the date of a district court decision finding non-infringement
• On the date of a Federal Circuit decision
• On the date of first commercial marketing by any first applicant
• On the date the 30-month stay expires

Correct Answer: On the date of first commercial marketing by any first applicant

Q13. Which is NOT typically a forfeiture event for 180-day exclusivity under the MMA?

• Failure to obtain tentative approval within 30 months (subject to exceptions)
• Withdrawal of the ANDA
• Amendment to change a Paragraph IV certification to Paragraph III
• FDA’s denial of a 505(q) citizen petition

Correct Answer: FDA’s denial of a 505(q) citizen petition

Q14. Pediatric exclusivity under Hatch-Waxman generally:

• Adds 6 months to listed patents and regulatory exclusivities, potentially delaying ANDA approval
• Provides an additional 3 years of market exclusivity for new indications
• Eliminates the need for bioequivalence studies in pediatric populations
• Applies only to orphan-designated drugs

Correct Answer: Adds 6 months to listed patents and regulatory exclusivities, potentially delaying ANDA approval

Q15. A suitability petition (505(j)(2)(C)) can allow an ANDA to reference an RLD when the generic product:

• Has a different active moiety than the RLD
• Differs in dosage form, strength, or route of administration within allowable changes
• Requires new clinical investigations essential for approval of the change
• Is a biologic referencing the Purple Book

Correct Answer: Differs in dosage form, strength, or route of administration within allowable changes

Q16. Under Hatch-Waxman, the research “safe harbor” (35 U.S.C. § 271(e)(1)) generally protects:

• All commercial marketing after approval
• Pre- and post-approval sales for compassionate use
• Activities reasonably related to generating data for FDA submissions
• Manufacture for export to non-U.S. markets

Correct Answer: Activities reasonably related to generating data for FDA submissions

Q17. Post-MMA, how many 30-month stays of approval can generally be imposed per ANDA based on patents listed at the time of ANDA submission?

• Unlimited, one for each asserted patent
• Two 30-month stays if new patents list during review
• Generally only one 30-month stay per ANDA
• No 30-month stay is possible after MMA

Correct Answer: Generally only one 30-month stay per ANDA

Q18. Patent term restoration (PTE) under Hatch-Waxman (35 U.S.C. § 156) may:

• Extend any patent by up to 10 years without limits
• Restore up to 5 years, with a maximum of 14 years of patent life post-approval
• Extend regulatory exclusivity by 5 years
• Apply only to method-of-use patents

Correct Answer: Restore up to 5 years, with a maximum of 14 years of patent life post-approval

Q19. The FDA must generally respond to a 505(q) citizen petition intended to delay generic entry within:

• 30 days
• 90 days
• 150 days
• 365 days

Correct Answer: 150 days

Q20. Which statement best differentiates Hatch-Waxman applicability for drug types?

• Hatch-Waxman governs both small molecules and biologics equally through the Orange Book
• Hatch-Waxman ANDA/505(b)(2) pathways apply to small molecules, while biologics follow BPCIA and the Purple Book
• Biologics use ANDA with bioequivalence in the same way as small molecules
• Only biologics receive 180-day exclusivity under Paragraph IV

Correct Answer: Hatch-Waxman ANDA/505(b)(2) pathways apply to small molecules, while biologics follow BPCIA and the Purple Book

Download